These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 863544)

  • 1. Cell kinetics and immunoegenicity of lymphoma cells treated with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DIC) in vivo.
    Silvestrini R; Testorelli C; Goldin A; Nicolin A
    Int J Cancer; 1977 May; 19(5):664-9. PubMed ID: 863544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosensitivity and histocompatibility antigens in drug-altered leukemic cells.
    Nicolin A; Franco P; Testorelli C; Goldin A
    Cancer Res; 1976 Jan; 36(1):222-7. PubMed ID: 1248001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic changes of L5178Y lymphoma after treatment with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide in vivo.
    Nicolin A; Spreafico F; Bonmassar E; Goldin A
    J Natl Cancer Inst; 1976 Jan; 56(1):89-93. PubMed ID: 1255754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro lymphocyte stimulation and the generation of cytotoxic lymphocytes with drug-induced antigenic lymphomas.
    Testorelli C; Franco P; Goldin A; Nicolin A
    Cancer Res; 1978 Mar; 38(3):830-4. PubMed ID: 75062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased immunogenicity of two lymphoma lines after drug treatment of athymic (nude) mice.
    Campanile F; Houchens DP; Gaston M; Goldin A; Bonmassar E
    J Natl Cancer Inst; 1975 Jul; 55(1):207-9. PubMed ID: 1159815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attempt to alter antigenic structure of normal tissues by treatment with dimethyl-triazeno-imidazole-carboxamide in vivo.
    Nicolin A; Fagnani R; Nicolotti G; Goldin A
    Experientia; 1976 Jun; 32(6):741-2. PubMed ID: 780128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo.
    Riccardi C; Fioretti MC; Giampietri A; Puccetti P; Goldin A
    Transplantation; 1978 Feb; 25(2):63-8. PubMed ID: 146282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic cross-reactivity of antigen(s) induced by drug treatment in two leukemic sublines.
    Nicolin A; Bini A; Di Padova F; Goldin A
    J Immunol; 1976 May; 116(5):1347-9. PubMed ID: 58028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-mediated immunogenic changes of virus-induced leukemia in vivo.
    Houchens DP; Bonmassar E; Gaston MR; Kende M; Goldin A
    Cancer Res; 1976 Apr; 36(4):1347-52. PubMed ID: 1260759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth inhibition of normal or drug-treated lymphoma cells in lethally irradiated mice.
    Riccardi C; Fioretti MC; Giampietri A; Puccetti P; Goldin A; Bonmassar E
    J Natl Cancer Inst; 1978 May; 60(5):1083-90. PubMed ID: 642028
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaccination of leukemic mice with viable drug-altered leukemic cells.
    Boerio D; Cavalli M; Marelli O; Veronese F; Nicolin A
    Ric Clin Lab; 1978; 8(3):127-33. PubMed ID: 746293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo.
    Romani L; Fioretti MC; Bonmassar E
    Transplantation; 1979 Sep; 28(3):218-22. PubMed ID: 494379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of the immunogenic properties of K36 lymphoma treated in vivo with 5(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC).
    Bonmassar A; Frati L; Fioretti MC; Romani L; Giampietri A; Goldin A
    Eur J Cancer (1965); 1979 Jul; 15(7):933-9. PubMed ID: 488153
    [No Abstract]   [Full Text] [Related]  

  • 14. Transplantation resistance of drug-treated allogeneic mice against murine lymphomas--II. Studies with various tumor-host combinations.
    Bonmassar A; Rivosecchi-Merletti P; Barzi A; Goldin A; Bonmassar E
    Int J Immunopharmacol; 1981; 3(4):391-9. PubMed ID: 7333720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Depression of the immune response to lymphoma allotransplant with the use of 5-(3,3-dimethyl-1-triazeno)-imidazol-4-carboxamide (DTIC)].
    Giampietri A; Puccetti P; Circolo A; Menconi E
    Boll Soc Ital Biol Sper; 1977 Jun; 53(11):922-6. PubMed ID: 597414
    [No Abstract]   [Full Text] [Related]  

  • 16. Changes of the immunogenic properties of a radiation-induced mouse lymphoma following treatment with antitumor drugs.
    Bonmassar E; Testorelli C; Franco P; Goldin A; Cudkowicz G
    Cancer Res; 1975 Aug; 35(8):1957-62. PubMed ID: 1149019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy.
    Giampietri A; Bonmassar A; Puccetti P; Circolo A; Goldin A; Bonmassar E
    Cancer Res; 1981 Feb; 41(2):681-7. PubMed ID: 7448813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity induced in vivo by DIC in relatively non-immunogenic leukemias.
    Nicolin A; Cavalli M; Missiroli A; Goldin A
    Eur J Cancer (1965); 1977 Mar; 13(3):235-9. PubMed ID: 862643
    [No Abstract]   [Full Text] [Related]  

  • 19. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
    Gordon WC; Prager MD
    Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transplantation resistance of drug-treated hybrid or allogeneic mice against murine lymphomas. I. Immunopharmacology studies.
    Bonmassar A; Riccardi C; Rivosecchi-Merletti P; Goldin A; Bonmassar E
    Int J Cancer; 1980 Dec; 26(6):819-29. PubMed ID: 6971268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.